⌘K
t
| TIDM | HEMO |
| Share Price | GBX 771.76-4.63% |
| Market Cap | £49.59m |
Hemogenyx Pharmaceuticals plc intends to re-appoint PKF Littlejohn LLP as its external auditor for the financial year ending December 2025 onwards, following a formal tender process overseen by the Audit Committee. This decision coincides with mandatory lead audit partner rotation and is subject to shareholder approval at the Company's 2026 Annual General Meeting.
| Date | 29 Aug 2025 |
| Time | 07:00:08 |
| Category | Capital structure |
| ID | 1349X |
29 August 2025
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Result of Audit Tender
Hemogenyx Pharmaceuticals plc (LSE: HEMO), is pleased to announce that following the conclusion of the formal tender process for the role of statutory auditor, it intends to re-appoint PKF Littlejohn LLP as external auditor for the financial year ending December 2025 onwards. This will coincide with the timing of the mandatory lead audit partner rotation.
The audit tender was conducted as a result of the requirement for public interest entities to undertake an audit tender at least every ten years. A thorough tender process, overseen by the Audit Committee, was undertaken and this proposed change of auditor follows a recommendation by the Audit Committee to the Board based on the outcome of the tender process.
Further details of the audit tender process and evaluation criteria will be included in the Group's 2025 Annual Report & Accounts. The appointment will be subject to shareholder approval at the Company's 2026 Annual General Meeting.
Enquiries:
|
Hemogenyx Pharmaceuticals plc |
|
|
Dr Vladislav Sandler, Chief Executive Officer & Co-Founder |
|
|
Peter Redmond, Director |
|
|
SP Angel Corporate Finance LLP |
Tel: +44 (0)20 3470 0470 |
|
Matthew Johnson, Vadim Alexandre, Adam Cowl
|
|
|
Peterhouse Capital Limited |
Tel: +44 (0)20 7469 0930 |
|
Lucy Williams, Duncan Vasey, Charles Goodfellow |
|
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City.
The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.